LifeMD Inc 8.875% Series A Preferred Stock

LFMDP

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference, which will be held October 9, 2025 at the Metropolitan Club in New York City. Management will hold one-on-one meetings with investors throughout the day.

NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

Enhanced Affiliated Pharmacy Capabilities Support Specialized Therapies, Seamless Patient Experience, and Margin Expansion Enhanced Affiliated Pharmacy Capabilities Support Specialized Therapies, Seamless Patient Experience, and Margin Expansion

LifeMD, Inc. (NASDAQ:LFMD ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Justin Schreiber - Chairman & CEO Marc Benathen - Chief Financial Officer Conference Call Participants Anderson Schock - B. Riley Securities, Inc., Research Division Jenny Shen - BTIG, LLC, Research Division Ryan Robert Meyers - Lake Street Capital Markets, LLC, Research Division Sarah Elizabeth James - Cantor Fitzgerald & Co., Research Division Steven Craig Dechert - KeyBanc Capital Markets Inc., Research Division Operator Good afternoon.

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced its participation in the Canaccord Genuity 45th Annual Growth Conference, which will be held August 12-14, 2025 at the InterContinental Boston. Management will participate in a fireside chat on Wednesday, August 13th at 8:30 a.m. Eastern time and will hold one-on-one meetings with investors on August 12-13.

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter Bundled Offer Includes Wegovy® at $199 and LifeMD's Virtual Weight Loss Program for a Total First-Month Cost of $299, $599 per Month Thereafter

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of May:

LifeMD, Inc. (NASDAQ:LFMD ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Justin Schreiber - Chairman and CEO Marc Benathen - Chief Financial Officer Conference Call Participants David Larsen - BTIG Sarah James - Cantor Fitzgerald Steve Dechert - KeyBanc Steven Valiquette - Mizuho Securities Yi Chen - H.C. Wainwright Anderson Schock - B.

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD's virtual care platform.